ERBB2 and breast carcinoma: Pathologic complete response (pCR) rates are highest in human epidermal growth factor receptor 2-positive (HER2+) and triple negative (TN) subtypes (40–89%), whereas lower rates are observed in hormone receptor-positive (HR+)/HER2-negative (HER2−) breast cancer (10–15%).3–11 As it is questionable whether surgical resection contributes to local control in patients with pCR, less invasive techniques than surgery to assess pCR in patients who underwent NST would be preferable.